EA200101133A1 - Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина - Google Patents

Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина

Info

Publication number
EA200101133A1
EA200101133A1 EA200101133A EA200101133A EA200101133A1 EA 200101133 A1 EA200101133 A1 EA 200101133A1 EA 200101133 A EA200101133 A EA 200101133A EA 200101133 A EA200101133 A EA 200101133A EA 200101133 A1 EA200101133 A1 EA 200101133A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloid
aggregation
inhibiting
visualizing
derivatives
Prior art date
Application number
EA200101133A
Other languages
English (en)
Other versions
EA004405B1 (ru
Inventor
Коринн Элизабет Оджелли-Зэфрэн
Йингджи Лай
Аннетт Тереза Сэккэб
Лари Кразуэлл Уокер
Original Assignee
Уорнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорнер-Ламберт Компани filed Critical Уорнер-Ламберт Компани
Publication of EA200101133A1 publication Critical patent/EA200101133A1/ru
Publication of EA004405B1 publication Critical patent/EA004405B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

В настоящем изобретении предложен способ лечения болезни Альцгеймера с использованием нового соединения формулы (I), где Х представляет собой фенил или замещенный фенил; Y представляет собой фенил, замещенный фенил, пиридил или замещенный пиридил. Предложен также способ ингибирования агрегации амилоидных белков с использованием соединения формулы (I) и способ визуализации амилоидных отложений с использованием производных изоиндолина.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101133A 1999-06-10 2000-05-31 Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина EA004405B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10
PCT/US2000/015073 WO2000076969A1 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (2)

Publication Number Publication Date
EA200101133A1 true EA200101133A1 (ru) 2002-06-27
EA004405B1 EA004405B1 (ru) 2004-04-29

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101133A EA004405B1 (ru) 1999-06-10 2000-05-31 Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина

Country Status (38)

Country Link
EP (1) EP1192131B1 (ru)
JP (1) JP2003502313A (ru)
KR (1) KR20020012266A (ru)
CN (1) CN1156445C (ru)
AP (1) AP1398A (ru)
AT (1) ATE272623T1 (ru)
AU (1) AU777747B2 (ru)
BG (1) BG106291A (ru)
BR (1) BR0011446A (ru)
CA (1) CA2373394A1 (ru)
CR (1) CR6530A (ru)
CZ (1) CZ20014366A3 (ru)
DE (1) DE60012742T2 (ru)
DK (1) DK1192131T3 (ru)
DZ (1) DZ3262A1 (ru)
EA (1) EA004405B1 (ru)
EE (1) EE200100666A (ru)
ES (1) ES2223531T3 (ru)
GE (1) GEP20043407B (ru)
HK (1) HK1046283B (ru)
HR (1) HRP20020027A2 (ru)
HU (1) HUP0201586A2 (ru)
IL (1) IL146455A0 (ru)
IS (1) IS6162A (ru)
MA (1) MA26807A1 (ru)
MX (1) MXPA01011112A (ru)
NO (1) NO20015992L (ru)
NZ (1) NZ515619A (ru)
OA (1) OA11958A (ru)
PL (1) PL352294A1 (ru)
PT (1) PT1192131E (ru)
SI (1) SI1192131T1 (ru)
SK (1) SK17622001A3 (ru)
TR (1) TR200200257T2 (ru)
UA (1) UA64842C2 (ru)
WO (1) WO2000076969A1 (ru)
YU (1) YU86801A (ru)
ZA (1) ZA200109164B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3252A1 (ru) * 1999-06-10 2000-12-21 Warner Lambert Co
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
PE20040844A1 (es) * 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
EP2102165A2 (en) * 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2307381B1 (en) * 2008-06-09 2021-01-13 Ludwig-Maximilians-Universität München New drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CN102439005B (zh) * 2009-05-07 2015-07-22 杨森制药公司 作为γ-分泌酶调节剂的取代的吲唑和氮杂-吲唑衍生物
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
IN2014MN00258A (ru) 2011-07-15 2015-09-25 Janssen Pharmaceuticals Inc
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
ES2838625T3 (es) * 2014-04-14 2021-07-02 Shanghai hengrui pharmaceutical co ltd Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos
SI3186241T1 (sl) * 2014-08-29 2021-03-31 Chdi Foundation, Inc. Sonde za slikanje Huntingtonovega proteina
PL3203840T3 (pl) 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2018064632A1 (en) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018107100A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3573615A4 (en) * 2017-01-28 2020-10-28 Kingchem Life Science LLC PROCESS FOR THE PREPARATION OF 5-PHENOXY-1 (3H) ISOBENZOFURANONE
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
TR200200257T2 (tr) 2002-06-21
PL352294A1 (en) 2003-08-11
UA64842C2 (ru) 2004-03-15
OA11958A (en) 2006-04-13
AP1398A (en) 2005-04-21
SK17622001A3 (sk) 2003-06-03
DE60012742D1 (de) 2004-09-09
CR6530A (es) 2004-03-24
AU5312000A (en) 2001-01-02
NO20015992L (no) 2002-02-06
AU777747B2 (en) 2004-10-28
KR20020012266A (ko) 2002-02-15
DK1192131T3 (da) 2004-12-13
DE60012742T2 (de) 2005-01-13
DZ3262A1 (fr) 2000-12-12
NZ515619A (en) 2003-05-30
EE200100666A (et) 2003-02-17
NO20015992D0 (no) 2001-12-07
CN1156445C (zh) 2004-07-07
ATE272623T1 (de) 2004-08-15
EP1192131B1 (en) 2004-08-04
SI1192131T1 (en) 2004-12-31
MXPA01011112A (es) 2002-06-04
HRP20020027A2 (en) 2005-02-28
EA004405B1 (ru) 2004-04-29
ZA200109164B (en) 2003-02-06
JP2003502313A (ja) 2003-01-21
CA2373394A1 (en) 2000-12-21
AP2002002389A0 (en) 2002-03-31
PT1192131E (pt) 2004-11-30
MA26807A1 (fr) 2004-12-20
WO2000076969A1 (en) 2000-12-21
HK1046283B (zh) 2005-01-07
GEP20043407B (en) 2004-05-10
IL146455A0 (en) 2002-07-25
IS6162A (is) 2001-11-15
CZ20014366A3 (cs) 2002-11-13
HUP0201586A2 (en) 2002-08-28
CN1355790A (zh) 2002-06-26
HK1046283A1 (en) 2003-01-03
YU86801A (sh) 2004-07-15
BR0011446A (pt) 2002-03-19
EP1192131A1 (en) 2002-04-03
BG106291A (bg) 2002-05-31
ES2223531T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
EA200101133A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина
EA200200976A1 (ru) Способ лечения или ингибирования полипов ободочной кишки
EA200300674A1 (ru) Получение гетероциклических сульфонамидных ингибиторов бета-амилоида
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA199900620A1 (ru) Фталазиноны
EA200200873A1 (ru) Новые пиперазиновые производные
EA200500472A1 (ru) Ацетил 2-гидрокси-1,3-диаминоалканы
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA200001102A1 (ru) Способ синтеза ингибиторов сох-2 (циклооксигеназы-2)
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
ATE231505T1 (de) Neue heterocyclische/cyclische amine
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
EA200101135A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
EA200000551A1 (ru) α-ГИДРОКСИ, -АМИНО И ГАЛОИДНЫЕ ПРОИЗВОДНЫЕ β-СУЛЬФОНИЛГИДРОКСАМОВЫХ КИСЛОТ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИКСНЫХ МЕТАЛЛОПРОТЕИНАЗ
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
EA200000094A1 (ru) Способ получения замещенного пергидроизоиндола
ATE304522T1 (de) Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
TR200103562T2 (tr) Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
EA200300516A1 (ru) Комбинация, включающая камптотецин и производные стильбена, для лечения рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU